Helicos BioSciences, which is developing genetic analysis technologies for research and drug discovery uses, lowered the anticipated price of its IPO again on Thursday. The company announced in its SEC filing that it anticipated a $9.00 price tag on its shares. Helicos had originally announced a $13-$15 price range, and then lowered it to $10-$11 on Wednesday. UBS is bookrunning the deal.
